Jacobio Pharmaceuticals Group Yönetim

Yönetim kriter kontrolleri 3/4

Jacobio Pharmaceuticals Group CEO'su Yinxiang Wang, Aug2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı CN¥ 3.42M olup, şirket hissesi ve opsiyonları dahil olmak üzere 77.3% maaş ve 22.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 13.63% ine doğrudan sahiptir ve bu hisseler HK$ 196.82M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 4.3 yıldır.

Anahtar bilgiler

Yinxiang Wang

İcra Kurulu Başkanı

CN¥3.4m

Toplam tazminat

CEO maaş yüzdesi	77.3%
CEO görev süresi	5.3yrs
CEO sahipliği	13.6%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31

Recent updates

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

May 29

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21

CEO Tazminat Analizi

Yinxiang Wang'un ücretlendirmesi Jacobio Pharmaceuticals Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥362m
Mar 31 2024	n/a	n/a	-CN¥361m
Dec 31 2023	CN¥3m	CN¥3m	-CN¥359m
Sep 30 2023	n/a	n/a	-CN¥385m
Jun 30 2023	n/a	n/a	-CN¥410m
Mar 31 2023	n/a	n/a	-CN¥391m
Dec 31 2022	CN¥4m	CN¥2m	-CN¥372m
Sep 30 2022	n/a	n/a	-CN¥332m
Jun 30 2022	n/a	n/a	-CN¥292m
Mar 31 2022	n/a	n/a	-CN¥297m
Dec 31 2021	CN¥4m	CN¥2m	-CN¥301m

Tazminat ve Piyasa: Yinxiang 'nin toplam tazminatı ($USD 479.54K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 359.95K ).

Tazminat ve Kazançlar: Yinxiang 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Yinxiang Wang (59 yo)

5.3yrs

Görev süresi

CN¥3,415,000

Tazminat

Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yinxiang Wang	Executive Chairman & CEO	5.3yrs	CN¥3.42m	13.63% HK$ 196.8m
Xiaojie Wang	Executive Director & President of Administration	9.2yrs	CN¥2.55m	2.91% HK$ 42.0m
Yunyan Hu	Executive VP & Executive Director	5.7yrs	CN¥2.51m	2.95% HK$ 42.6m
Tao Yang	Vice President of Human Resources	no data	Veri yok	Veri yok
Andrea Wang-Gillam	Executive VP	4.3yrs	Veri yok	Veri yok
Yanping Wang	Executive Vice President of Non-Clinical R&D	no data	Veri yok	Veri yok
Haijun Wang	Senior Vice President of Information & Data Management	no data	Veri yok	Veri yok
Yuli Ding	Executive Vice President of Clinical Development	no data	Veri yok	Veri yok
Qing Xue	Joint Company Secretary	4.3yrs	Veri yok	Veri yok
Ming Fai Chung	Joint Company Secretary	2.3yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 1167 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yinxiang Wang	Executive Chairman & CEO	6.4yrs	CN¥3.42m	13.63% HK$ 196.8m
Xiaojie Wang	Executive Director & President of Administration	6.3yrs	CN¥2.55m	2.91% HK$ 42.0m
Yunyan Hu	Executive VP & Executive Director	6.3yrs	CN¥2.51m	2.95% HK$ 42.6m
Ge Wu	Independent Non-Executive Director	4.3yrs	CN¥200.00k	Veri yok
Ruilin Song	Independent Non-Executive Director	4.3yrs	CN¥400.00k	Veri yok
Te-li Chen	Non Executive Director	4.3yrs	Veri yok	Veri yok
Bai Lu	Independent Non-Executive Director	1.7yrs	CN¥150.00k	Veri yok

4.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1167 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Jacobio Pharmaceuticals Group Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jacobio Pharmaceuticals Group Co., Ltd. Announces Board Changes

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Executive Chairman & CEO recently bought HK$594k worth of stock

Less than half of directors are independent

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Recent updates

Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024

First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73

New minor risk - Revenue size

Jacobio Pharmaceuticals Group Co., Ltd. Announces Board Changes

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with Glecirasib

Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer

Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Full year 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.49 loss in FY 2022)

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI

Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo

Executive Chairman & CEO recently bought HK$594k worth of stock

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients

Jacobio Pharmaceuticals Group Co., Ltd. announced that it expects to receive CNY 150 million in funding from Beijing E-Town International Investment & Development Co., Ltd.

Consensus revenue estimates fall by 86%

Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval for PARP7 Inhibitor JAB-26766 in China

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharma Completes First Patient Dosage of Aurora Inhibitor JAB-2485 in U.S

Jacobio's Kras G12c Inhibitor JAB-21822 Was Granted Breakthrough Therapy Designations by China Cde

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

Less than half of directors are independent

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

Jacobio Pharma Completes First Patient Dosage of Cd73 Mab Jab-Bx102 in China

Jacobio Pharmaceuticals Group Co., Ltd. Announces First Patient Dosed with JAB-21822 in the Phase IIa Trial on KRAS G12C and STK11 Co-Mutation

Consensus revenue estimates fall by 12%

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jacobio Pharma will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Less than half of directors are independent

Board Member recently bought HK$91k worth of stock

Senior VP & Executive Director recently bought HK$150k worth of stock

Senior VP & Executive Director recently bought HK$336k worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Senior VP & Executive Director recently bought HK$1.6m worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. Announces Investigational New Drug Approval of Aurora A Inhibitor JAB-2485 from Food and Drug Administration of the United States

Jacobio Pharma Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of Kras G12c Inhibitor for Solid Tumor

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment

Jacobio Announces FDA Approves IND Application to Develop KRAS G12c Inhibitor

Joint Company Secretary has left the company

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Jacobio Pharmaceuticals Group Co., Ltd. Together with Its Subsidiaries Receive Two Investigational New Drug (The "IND") Approvals to Initiate Clinical Trials for Its Shp2 Inhibitors

Jacobio Pharmaceuticals Group Co., Ltd. has completed an IPO in the amount of HKD 1.350665 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi